Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0035 0.001% in Dry Eye Disease (DELTA-1)
NCT03527212Phase 3Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing SJP-0035 0.001% with Placebo (2 arms). Primary endpoint: Corneal fluorescein staining at Week 5. Started Aug 2018; status: completed.
02
Drugs
fonadelpar
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03527212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527212.